CoreAge Rx vs Layla
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Layla head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 71 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.
That doesn't make Layla a bad call — it's best for readers who can obtain a complete product-specific quote and the governing glp-1 payment agreement before enrolling. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Compare | CoreAge Rx | Layla |
|---|---|---|
| Brief Score | 94/100 (A) | 71/100 (C) |
| Semaglutide | From $79/mo Annual offer: 12 months paid upfront, from $948. Main site: from $99/mo; confirm the selected offer. Full price detailsFrom $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo | Confirm product and supply period Visible branded choices and a generic $1,299 starting figure do not establish a semaglutide supply period or complete quote. Full price detailsCurrent semaglutide formulation and complete medication quote unknown; visible branded options and an undefined $1,299 GLP-1 starting figure require confirmation; earlier listing: From $237/mo (all doses, compounded) |
| Tirzepatide | From $129/mo Annual offer: 12 months paid upfront, from $1,548. Main site: from $149/mo; confirm the selected offer. Full price detailsFrom $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo | Current tirzepatide quote unknown Visible branded options lack a molecule-specific total. The generic $1,299 GLP-1 figure has no clear supply period. Full price detailsCurrent tirzepatide formulation, supply and complete quote unknown; branded options displayed without a molecule-specific public total; earlier listing: From $199/mo (all doses, compounded) |
| Coverage | US only; restrictions by state, confirmed at intake | Selected treatment availability depends on patient location, clinician licensing and pharmacy eligibility; confirm your state |
| Brand-name access | Not confirmed | The visible page lists named branded choices; exact product, pharmacy and complete quote remain unconfirmed. |
| Oral / sublingual | Injection only | Unconfirmed |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.
Layla: Visible page lists branded choices and a $1,299 generic starting figure with no clear supply period. Complete medication/formulation quotes remain unconfirmed.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.